BACKGROUND: The bcl-2 oncoprotein is suggested to be directly involved in the emergence of drug resistance by disrupting or delaying the apoptotic program and promoting tumor survival. PATIENTS AND METHODS: In order to define the clinical relevance of the bcl-2 mRNA expression in acute myeloid leukemia (AML) and its correlation to therapy outcome and prognosis, we analyzed 219 AML bone marrow (BM) samples, including 119 patients with de novo AML at presentation, 37 with AML following myelodysplastic syndrome (MDS), as well as 42 BM samples of AML in relapse and 21 in complete remission (CR) using RT-PCR. For performing quantitative measurements of bcl-2 mRNA, we developed a quantitative RT-PCR. RESULTS: Bcl-2 mRNA was detectable in 133 of 156 (84%) patients at diagnosis and 40 of 42 (95%) at relapse. AML patients with high bcl-2 mRNA expression achieved lower CR rates than those with no or low expression. Concerning the long-term outcome, the overall (OS) and disease-free survival (DFS) was significantly worse in AML patients with high expression levels of bcl-2 mRNA. The three-year OS for all newly diagnosed AML patients was 49% and 10% (P = 0.028), respectively, and 71% and 15% (P = 0.0004) for patients < 60 years. Comparable significant differences were observed for the DFS. In AML following MDS and patients > 60 years, the bcl-2 expression was not associated with remission rate or survival. CONCLUSIONS: The expression of bcl-2 mRNA may serve as a prognostic factor predicting remission outcome and long-term prognosis in AML.
BACKGROUND: The bcl-2 oncoprotein is suggested to be directly involved in the emergence of drug resistance by disrupting or delaying the apoptotic program and promoting tumor survival. PATIENTS AND METHODS: In order to define the clinical relevance of the bcl-2 mRNA expression in acute myeloid leukemia (AML) and its correlation to therapy outcome and prognosis, we analyzed 219 AML bone marrow (BM) samples, including 119 patients with de novo AML at presentation, 37 with AML following myelodysplastic syndrome (MDS), as well as 42 BM samples of AML in relapse and 21 in complete remission (CR) using RT-PCR. For performing quantitative measurements of bcl-2 mRNA, we developed a quantitative RT-PCR. RESULTS:Bcl-2 mRNA was detectable in 133 of 156 (84%) patients at diagnosis and 40 of 42 (95%) at relapse. AMLpatients with high bcl-2 mRNA expression achieved lower CR rates than those with no or low expression. Concerning the long-term outcome, the overall (OS) and disease-free survival (DFS) was significantly worse in AMLpatients with high expression levels of bcl-2 mRNA. The three-year OS for all newly diagnosed AMLpatients was 49% and 10% (P = 0.028), respectively, and 71% and 15% (P = 0.0004) for patients < 60 years. Comparable significant differences were observed for the DFS. In AML following MDS and patients > 60 years, the bcl-2 expression was not associated with remission rate or survival. CONCLUSIONS: The expression of bcl-2 mRNA may serve as a prognostic factor predicting remission outcome and long-term prognosis in AML.
Authors: C Ustün; M Beksac; K Dalva; H Koc; N Konuk; O Ilhan; M Ozcan; P Topcuoglu; D Sertkaya; M Hayran Journal: Med Oncol Date: 2002 Impact factor: 3.064
Authors: Ali Fendri; Christos K Kontos; Abdelmajid Khabir; Raja Mokdad-Gargouri; Alexandros Ardavanis; Andreas Scorilas Journal: Tumour Biol Date: 2010-06-01
Authors: Weiguo Zhang; Vivian R Ruvolo; Chen Gao; Liran Zhou; William Bornmann; Twee Tsao; Wendy D Schober; Paul Smith; Sylvie Guichard; Marina Konopleva; Michael Andreeff Journal: Mol Cancer Ther Date: 2014-04-16 Impact factor: 6.261
Authors: Shibu Thomas; Bridget A Quinn; Swadesh K Das; Rupesh Dash; Luni Emdad; Santanu Dasgupta; Xiang-Yang Wang; Paul Dent; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher Journal: Expert Opin Ther Targets Date: 2012-11-22 Impact factor: 6.902